<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37319115</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1471-4159</ISSN><JournalIssue CitedMedium="Internet"><Volume>166</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of neurochemistry</Title><ISOAbbreviation>J Neurochem</ISOAbbreviation></Journal><ArticleTitle>C9orf72 poly-PR helps p53 escape from the ubiquitin-proteasome system and promotes its stability.</ArticleTitle><Pagination><StartPage>389</StartPage><EndPage>402</EndPage><MedlinePgn>389-402</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jnc.15872</ELocationID><Abstract><AbstractText>C9orf72-derived dipeptide repeats (DPRs) proteins have been regarded as the pathogenic cause of neurodegeneration in amyotrophic lateral sclerosis and frontotemporal dementia (C9-ALS/FTD). As the most toxic DPRs in C9-ALS/FTD, poly-proline-arginine (poly-PR) is associated with the stability and accumulation of p53, which consequently induces neurodegeneration. However, the exact molecular mechanism via which C9orf72 poly-PR stabilizes p53 remains unclear. In this study, we showed that C9orf72 poly-PR induces not only neuronal damage but also p53 accumulation and p53 downstream gene activation in primary neurons. C9orf72 (PR)<sub>50</sub> also slows down p53 protein turnover without affecting the p53 transcription level and thus promotes its stability in N2a cells. Interestingly, the ubiquitin-proteasome system but not the autophagy function was impaired in (PR)<sub>50</sub> transfected N2a cells, resulting in defective p53 degradation. Moreover, we found that (PR)<sub>50</sub> induces mdm2 mistranslocation from the nucleus to the cytoplasm and competitively binds to p53, reducing mdm2-p53 interactions in the nucleus in two different (PR)<sub>50</sub> transfected cells. Our data strongly indicate that (PR)<sub>50</sub> reduces mdm2-p53 interactions and causes p53 to escape from the ubiquitin-proteasome system, promoting its stability and accumulation. Inhibiting or at least downregulating (PR)<sub>50</sub> binding with p53 may be therapeutically exploited for the treatment of C9-ALS/FTD.</AbstractText><CopyrightInformation>&#xa9; 2023 International Society for Neurochemistry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Fumin</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-9261-4370</Identifier><AffiliationInfo><Affiliation>Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education Ministry/Hubei Province of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahaman</LastName><ForeName>Yacoubou Abdoul Razak</ForeName><Initials>YAR</Initials><Identifier Source="ORCID">0000-0002-9278-4185</Identifier><AffiliationInfo><Affiliation>Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education Ministry/Hubei Province of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education Ministry/Hubei Province of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jian-Zhi</ForeName><Initials>JZ</Initials><Identifier Source="ORCID">0000-0002-6750-1577</Identifier><AffiliationInfo><Affiliation>Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education Ministry/Hubei Province of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Co-innovation Center of Neuroregeneration, Nantong University, Nantong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Rong</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-7477-6520</Identifier><AffiliationInfo><Affiliation>Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education Ministry/Hubei Province of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Co-innovation Center of Neuroregeneration, Nantong University, Nantong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurochemistry, Inge Grundke-Iqbal Research Floor, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaochuan</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0001-8207-0042</Identifier><AffiliationInfo><Affiliation>Department of Pathophysiology, School of Basic Medicine, Key Laboratory of Education Ministry/Hubei Province of China for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Co-innovation Center of Neuroregeneration, Nantong University, Nantong, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurochem</MedlineTA><NlmUniqueID>2985190R</NlmUniqueID><ISSNLinking>0022-3042</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.25.1</RegistryNumber><NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025801">Ubiquitin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025801" MajorTopicYN="N">Ubiquitin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C9orf72 PR</Keyword><Keyword MajorTopicYN="N">FTD/ALS</Keyword><Keyword MajorTopicYN="N">mdm2</Keyword><Keyword MajorTopicYN="N">p53</Keyword><Keyword MajorTopicYN="N">ubiquition-proteasome pathway</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>15</Day><Hour>19</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>15</Day><Hour>13</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37319115</ArticleId><ArticleId IdType="doi">10.1111/jnc.15872</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Balendra, R., &amp; Isaacs, A. M. (2018). C9orf72-mediated ALS and FTD: Multiple pathways to disease. Nature Reviews Neurology, 14(9), 544-558. https://doi.org/10.1038/s41582-018-0047-2</Citation></Reference><Reference><Citation>Beckers, J., Tharkeshwar, A. K., &amp; Van Damme, P. (2021). C9orf72 ALS-FTD: Recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels. Autophagy, 17(11), 3306-3322. https://doi.org/10.1080/15548627.2021.1872189</Citation></Reference><Reference><Citation>Blondel-Tepaz, E., Leverve, M., Sokrat, B., Paradis, J. S., Kosic, M., Saha, K., Auffray, C., Lima-Fernandes, E., Zamborlini, A., Poupon, A., Gaboury, L., Findlay, J., Baillie, G. S., Enslen, H., Bouvier, M., Angers, S., Marullo, S., &amp; Scott, M. G. H. (2021). The RanBP2/RanGAP1-SUMO complex gates beta-arrestin2 nuclear entry to regulate the Mdm2-p53 signaling axis. Oncogene, 40(12), 2243-2257. https://doi.org/10.1038/s41388-021-01704-w</Citation></Reference><Reference><Citation>Braems, E., Swinnen, B., &amp; Van Den Bosch, L. (2020). C9orf72 loss-of-function: A trivial, stand-alone or additive mechanism in C9 ALS/FTD? Acta Neuropathologica, 140(5), 625-643. https://doi.org/10.1007/s00401-020-02214-x</Citation></Reference><Reference><Citation>Brooks, C. L., &amp; Gu, W. (2003). Ubiquitination, phosphorylation and acetylation: The molecular basis for p53 regulation. Current Opinion in Cell Biology, 15(2), 164-171. https://doi.org/10.1016/s0955-0674(03)00003-6</Citation></Reference><Reference><Citation>Dai, C., &amp; Gu, W. (2010). p53 post-translational modification: Deregulated in tumorigenesis. Trends in Molecular Medicine, 16(11), 528-536. https://doi.org/10.1016/j.molmed.2010.09.002</Citation></Reference><Reference><Citation>DeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. A., Flynn, H., Adamson, J., Kouri, N., Wojtas, A., Sengdy, P., Hsiung, G. Y., Karydas, A., Seeley, W. W., Josephs, K. A., Coppola, G., Geschwind, D. H., &#x2026; Rademakers, R. (2011). Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron, 72(2), 245-256. https://doi.org/10.1016/j.neuron.2011.09.011</Citation></Reference><Reference><Citation>do Patrocinio, A. B., Rodrigues, V., &amp; Guidi Magalhaes, L. (2022). P53: Stability from the ubiquitin-proteasome system and specific 26S proteasome inhibitors. ACS Omega, 7(5), 3836-3843. https://doi.org/10.1021/acsomega.1c04726</Citation></Reference><Reference><Citation>Fare, C. M., &amp; Shorter, J. (2021). Open access: A role for p53 in c9ALS/FTD? Trends in Genetics, 37(5), 404-406. https://doi.org/10.1016/j.tig.2021.01.008</Citation></Reference><Reference><Citation>Feeley, K. P., Adams, C. M., Mitra, R., &amp; Eischen, C. M. (2017). Mdm2 is required for survival and growth of p53-deficient cancer cells. Cancer Research, 77(14), 3823-3833. https://doi.org/10.1158/0008-5472.CAN-17-0809</Citation></Reference><Reference><Citation>Foggetti, G., Ottaggio, L., Russo, D., Mazzitelli, C., Monti, P., Degan, P., Miele, M., Fronza, G., &amp; Menichini, P. (2019). Autophagy induced by SAHA affects mutant P53 degradation and cancer cell survival. Bioscience Reports, 39(2). https://doi.org/10.1042/BSR20181345</Citation></Reference><Reference><Citation>Freibaum, B. D., Lu, Y., Lopez-Gonzalez, R., Kim, N. C., Almeida, S., Lee, K. H., Badders, N., Valentine, M., Miller, B. L., Wong, P. C., Petrucelli, L., Kim, H. J., Gao, F. B., &amp; Taylor, J. P. (2015). GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature, 525(7567), 129-133. https://doi.org/10.1038/nature14974</Citation></Reference><Reference><Citation>Gao, J., Mewborne, Q. T., Girdhar, A., Sheth, U., Coyne, A. N., Punathil, R., Kang, B. G., Dasovich, M., Veire, A., DeJesus Hernandez, M., Liu, S., Shi, Z., Dafinca, R., Fouquerel, E., Talbot, K., Kam, T. I., Zhang, Y. J., Dickson, D., Petrucelli, L., &#x2026; Zhang, K. (2022). Poly(ADP-ribose) promotes toxicity of C9ORF72 arginine-rich dipeptide repeat proteins. Science Translational Medicine, 14(662), eabq3215. https://doi.org/10.1126/scitranslmed.abq3215</Citation></Reference><Reference><Citation>Geyer, R. K., Yu, Z. K., &amp; Maki, C. G. (2000). The MDM2 RING-finger domain is required to promote p53 nuclear export. Nature Cell Biology, 2(9), 569-573. https://doi.org/10.1038/35023507</Citation></Reference><Reference><Citation>Gupta, R., Lan, M., Mojsilovic-Petrovic, J., Choi, W. H., Safren, N., Barmada, S., Lee, M. J., &amp; Kalb, R. (2017). The proline/arginine dipeptide from hexanucleotide repeat expanded C9ORF72 inhibits the proteasome. eNeuro, 4(1), ENEURO.0249-16.2017. https://doi.org/10.1523/ENEURO.0249-16.2017</Citation></Reference><Reference><Citation>Hao, Z., Liu, L., Tao, Z., Wang, R., Ren, H., Sun, H., Lin, Z., Zhang, Z., Mu, C., Zhou, J., &amp; Wang, G. (2019). Motor dysfunction and neurodegeneration in a C9orf72 mouse line expressing poly-PR. Nature Communications, 10(1), 2906. https://doi.org/10.1038/s41467-019-10956-w</Citation></Reference><Reference><Citation>Haupt, Y., Maya, R., Kazaz, A., &amp; Oren, M. (1997). Mdm2 promotes the rapid degradation of p53. Nature, 387(6630), 296-299. https://doi.org/10.1038/387296a0</Citation></Reference><Reference><Citation>Jiang, M., Chiu, S. Y., &amp; Hsu, W. (2011). SUMO-specific protease 2 in Mdm2-mediated regulation of p53. Cell Death &amp; Differentiation, 18(6), 1005-1015. https://doi.org/10.1038/cdd.2010.168</Citation></Reference><Reference><Citation>Kruse, J. P., &amp; Gu, W. (2009). MSL2 promotes Mdm2-independent cytoplasmic localization of p53. Journal of Biological Chemistry, 284(5), 3250-3263. https://doi.org/10.1074/jbc.M805658200</Citation></Reference><Reference><Citation>Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., &amp; Pavletich, N. P. (1996). Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science, 274(5289), 948-953. https://doi.org/10.1126/science.274.5289.948</Citation></Reference><Reference><Citation>Kwon, I., Xiang, S., Kato, M., Wu, L., Theodoropoulos, P., Wang, T., Kim, J., Yun, J., Xie, Y., &amp; McKnight, S. (2014). Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science, 345(6201), 1139-1145. https://doi.org/10.1126/science.1254917</Citation></Reference><Reference><Citation>Leskela, S., Huber, N., Hoffmann, D., Rostalski, H., Remes, A. M., Takalo, M., Hiltunen, M., &amp; Haapasalo, A. (2021). Expression of C9orf72 hexanucleotide repeat expansion leads to formation of RNA foci and dipeptide repeat proteins but does not influence autophagy or proteasomal function in neuronal cells. Biochimica et Biophysica Acta, 1868(7), 119021. https://doi.org/10.1016/j.bbamcr.2021.119021</Citation></Reference><Reference><Citation>Ling, J. P., Pletnikova, O., Troncoso, J. C., &amp; Wong, P. C. (2015). TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science, 349(6248), 650-655. https://doi.org/10.1126/science.aab0983</Citation></Reference><Reference><Citation>Liu, J., Guan, D., Dong, M., Yang, J., Wei, H., Liang, Q., Song, L., Xu, L., Bai, J., Liu, C., Mao, J., Zhang, Q., Zhou, J., Wu, X., Wang, M., &amp; Cong, Y. S. (2020). UFMylation maintains tumour suppressor p53 stability by antagonizing its ubiquitination. Nature Cell Biology, 22(9), 1056-1063. https://doi.org/10.1038/s41556-020-0559-z</Citation></Reference><Reference><Citation>Mackenzie, I. R., Frick, P., Gr&#xe4;sser, F. A., Gendron, T. F., Petrucelli, L., Cashman, N. R., Edbauer, D., Kremmer, E., Prudlo, J., Troost, D., &amp; Neumann, M. (2015). Quantitative analysis and clinico-pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers. Acta Neuropathologica, 130(6), 845-861. https://doi.org/10.1007/s00401-015-1476-2</Citation></Reference><Reference><Citation>Maor-Nof, M., Shipony, Z., Lopez-Gonzalez, R., Nakayama, L., Zhang, Y. J., Couthouis, J., Blum, J. A., Castruita, P. A., Linares, G. R., Ruan, K., Ramaswami, G., Simon, D. J., Nof, A., Santana, M., Han, K., Sinnott-Armstrong, N., Bassik, M. C., Geschwind, D. H., Tessier-Lavigne, M., &#x2026; Gitler, A. D. (2021). p53 is a central regulator driving neurodegeneration caused by C9orf72 poly(PR). Cell, 184(3), 689-708.e620. https://doi.org/10.1016/j.cell.2020.12.025</Citation></Reference><Reference><Citation>Meek, D. W. (2009). Tumour suppression by p53: A role for the DNA damage response? Nature Reviews Cancer, 9(10), 714-723. https://doi.org/10.1038/nrc2716</Citation></Reference><Reference><Citation>Mizielinska, S., Gr&#xf6;nke, S., Niccoli, T., Ridler, C. E., Clayton, E. L., Devoy, A., Moens, T., Norona, F. E., Woollacott, I. O. C., Pietrzyk, J., Cleverley, K., Nicoll, A. J., Pickering-Brown, S., Dols, J., Cabecinha, M., Hendrich, O., Fratta, P., Fisher, E. M. C., Partridge, L., &amp; Isaacs, A. M. (2014). C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science, 345(6201), 1192-1194. https://doi.org/10.1126/science.1256800</Citation></Reference><Reference><Citation>Nanaura, H., Kawamukai, H., Fujiwara, A., Uehara, T., Aiba, Y., Nakanishi, M., Shiota, T., Hibino, M., Wiriyasermkul, P., Kikuchi, S., Nagata, R., Matsubayashi, M., Shinkai, Y., Niwa, T., Mannen, T., Morikawa, N., Iguchi, N., Kiriyama, T., Morishima, K., &#x2026; Mori, E. (2021). C9orf72-derived arginine-rich poly-dipeptides impede phase modifiers. Nature Communications, 12(1), 5301. https://doi.org/10.1038/s41467-021-25560-0</Citation></Reference><Reference><Citation>Nguyen, L., Montrasio, F., Pattamatta, A., Tusi, S. K., Bardhi, O., Meyer, K. D., Hayes, L., Nakamura, K., Banez-Coronel, M., Coyne, A., Guo, S., Laboissonniere, L. A., Gu, Y., Narayanan, S., Smith, B., Nitsch, R. M., Kankel, M. W., Rushe, M., Rothstein, J., &#x2026; Ranum, L. P. W. (2020). Antibody therapy targeting RAN proteins rescues C9 ALS/FTD phenotypes in C9orf72 mouse model. Neuron, 105(4), 645-662.e11. https://doi.org/10.1016/j.neuron.2019.11.007</Citation></Reference><Reference><Citation>Pohl, C., &amp; Dikic, I. (2019). Cellular quality control by the ubiquitin-proteasome system and autophagy. Science, 366(6467), 818-822. https://doi.org/10.1126/science.aax3769</Citation></Reference><Reference><Citation>Reed, S. M., &amp; Quelle, D. E. (2014). p53 acetylation: Regulation and consequences. Cancers (Basel), 7(1), 30-69. https://doi.org/10.3390/cancers7010030</Citation></Reference><Reference><Citation>Rufini, A., Tucci, P., Celardo, I., &amp; Melino, G. (2013). Senescence and aging: The critical roles of p53. Oncogene, 32(43), 5129-5143. https://doi.org/10.1038/onc.2012.640</Citation></Reference><Reference><Citation>Schwartz, D., &amp; Rotter, V. (1998). p53-dependent cell cycle control: response to genotoxic stress. Seminars in Cancer Biology, 8(5), 325-336. https://doi.org/10.1006/scbi.1998.0095</Citation></Reference><Reference><Citation>Shan, B., Li, D. W., Bruschweiler-Li, L., &amp; Bruschweiler, R. (2012). Competitive binding between dynamic p53 transactivation subdomains to human MDM2 protein: Implications for regulating the p53.MDM2/MDMX interaction. Journal of Biological Chemistry, 287(36), 30376-30384. https://doi.org/10.1074/jbc.M112.369793</Citation></Reference><Reference><Citation>Singh, S. R., Meyer-Jens, M., Alizoti, E., Bacon, W. C., Davis, G., Osinska, H., Gulick, J., Reischmann-D&#xfc;sener, S., Orthey, E., McLendon, P., Molkentin, J. D., Schlossarek, S., Robbins, J., &amp; Carrier, L. (2021). A high-throughput screening identifies ZNF418 as a novel regulator of the ubiquitin-proteasome system and autophagy-lysosomal pathway. Autophagy, 17(10), 3124-3139. https://doi.org/10.1080/15548627.2020.1856493</Citation></Reference><Reference><Citation>Solomon, H., Br&#xe4;uning, B., Fainer, I., Ben-Nissan, G., Rabani, S., Goldfinger, N., Moscovitz, O., Shakked, Z., Rotter, V., &amp; Sharon, M. (2017). Post-translational regulation of p53 function through 20S proteasome-mediated cleavage. Cell Death and Differentiation, 24(12), 2187-2198. https://doi.org/10.1038/cdd.2017.139</Citation></Reference><Reference><Citation>Usluer, S., Spreitzer, E., Bourgeois, B., &amp; Madl, T. (2021). p53 transactivation domain mediates binding and phase separation with poly-PR/GR. International Journal of Molecular Sciences, 22(21). https://doi.org/10.3390/ijms222111431</Citation></Reference><Reference><Citation>Wang, X., Simpson, E. R., &amp; Brown, K. A. (2015). p53: Protection against tumor growth beyond effects on cell cycle and apoptosis. Cancer Research, 75(23), 5001-5007. https://doi.org/10.1158/0008-5472.CAN-15-0563</Citation></Reference><Reference><Citation>Yuan, J., Luo, K., Zhang, L., Cheville, J. C., &amp; Lou, Z. (2010). USP10 regulates p53 localization and stability by deubiquitinating p53. Cell, 140(3), 384-396. https://doi.org/10.1016/j.cell.2009.12.032</Citation></Reference><Reference><Citation>Zhang, K., Donnelly, C. J., Haeusler, A. R., Grima, J. C., Machamer, J. B., Steinwald, P., Daley, E. L., Miller, S. J., Cunningham, K. M., Vidensky, S., Gupta, S., Thomas, M. A., Hong, I., Chiu, S. L., Huganir, R. L., Ostrow, L. W., Matunis, M. J., Wang, J., Sattler, R., &#x2026; Rothstein, J. D. (2015). The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature, 525(7567), 56-61. https://doi.org/10.1038/nature14973</Citation></Reference><Reference><Citation>Zhang, K., Wang, A., Zhong, K., Qi, S., Wei, C., Shu, X., Tu, W. Y., Xu, W., Xia, C., Xiao, Y., Chen, A., Bai, L., Zhang, J., Luo, B., Wang, W., &amp; Shen, C. (2021). UBQLN2-HSP70 axis reduces poly-Gly-Ala aggregates and alleviates behavioral defects in the C9ORF72 animal model. Neuron, 109(12), 1949-1962.e6. https://doi.org/10.1016/j.neuron.2021.04.023</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>